Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy
- 6 October 2022
- journal article
- research article
- Published by Elsevier in Brain and Development
- Vol. 45 (1) , 2-7
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophyOrphanet Journal of Rare Diseases, 2021
- Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophyJournal of Pharmacological Sciences, 2020
- Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammationJournal of Neuroinflammation, 2020
- Cerebrospinal fluid from patients with amyotrophic lateral sclerosis inhibits sonic hedgehog functionPLOS ONE, 2017
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation studyThe Lancet, 2016
- Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical TrialsJournal of Alzheimer’s Disease, 2012
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular AtrophyScience Translational Medicine, 2011
- Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosisActa Neurologica Scandinavica, 2010
- Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementiaEuropean Journal of Neuroscience, 2006